The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...

Clinical trials are more connected and more closely examined than ever. Inspection readiness isn’t a last-minute document ...

The startup, which is backed by a dozen investors including Merck & Co., claims its novel “linkers” can help address some of ...

The new fund will mostly support biotechs making new drugs, with investments spanning from initial financings to follow-on ...

Korro’s lead program for alpha-1 antitrypsin deficiency wasn’t as potent as anticipated, leading the company to change course ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...

Elevidys now has a “boxed” warning and is no longer available for Duchenne patients who can’t walk. Elsewhere, Nuvalent and Zymeworks unveiled data for targeted cancer drugs.

The decision, issued without the input of an official advisory committee, revises long-held labeling on the drugs cautioning ...

Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying ...